Access to disease modifying treatments for rheumatoid arthritis patients

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Furst, D E ^a   Breedveld, F C ^a   Burmester, G R ^a   Crofford, L ^a   Emery, P ^a   Feldman, M ^a   Kalden, J R ^a   Kavanaugh, A ^a   Keystone, E ^a   Lipsky, P E ^a   Maini, R N ^a   Moreland, L ^a   Smolen, J S ^a   Van De Putte, L ^a   Vischer, T ^a   Weinblatt, M ^a   Weissman, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING AGENT; TUMOR NECROSIS FACTOR;

DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; HUMAN; IMMUNOPHARMACOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PATIENT SELECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032732109     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993;36:1681-90.
2. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a antibody cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
3. Maini RN, Elliott MJ, Charles PJ, et al. Immunological intervention reveals reciprocal roles for TNFa and IL-10 in rheumatoid arthritis and SLE. Springer Semin Immunopathol 1994;6:327-36.
4. Maini RN, Elliott MJ, Brennan FM, et al. Monoclonal anti-TNFa antibody as a probe of pathogenesis is and therapy of rheumatoid disease. Immunol Rev 1995;144:195-223.
5. Feldmann M, Elliott MJ, Woody JN, et al. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350.
6. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
7. Kalden-Nemeth D, Grebmeier J, Antoni C, et al. NMR monitoring of rheumatoid arthritis patients receiving anti-TNFa monoclonal antibody therapy. Rheumatol Int 1997;16:249-55.
8. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
9. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic cascular endothelial growth factor by tumor necrosis factor a and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
10. Moreland L. Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:579-91.
11. Fenner H. Immunopharmacologic profile and therapeutic prospects of anti-TNF-alpha therapy. Z Rheumatol 1998;57:294-7.
12. Felson D, Lafyatis R, Korn J. Rheumatology. Biologic agents -is the promise realised? Lancet 1998;352 (suppl 4):s25.
13. Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:593-614.
14. Anonymous. New drugs for rheumatoid arthritis. Med Lett Drugs Ther 1998; 40:110-12.
15. Goldenberg MM. Entanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999;21:75-87.
16. Weinblatt E, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340: 253-9.